Tumor infiltrating lymphocyte therapy for ovarian cancer and renal cell carcinoma

Area of Science:

• Oncology
• Immunology
• Cancer Therapy

Background:

• Adoptive cell transfer (ACT) therapy, particularly with tumor-infiltrating lymphocytes (TILs), is a promising personalized cancer immunotherapy.
• TILs may target patient-specific mutations (neoantigens) driving tumor regression, with higher mutation burdens correlating with T-cell presence.
• While effective in melanoma, TIL therapy has shown limited success in other solid tumors historically.

Purpose of the Study:

• To summarize early clinical data on TIL-based ACT for renal cell carcinoma (RCC) and ovarian cancer (OC).
• To describe recent advances in the characterization and application of TIL therapy for these specific cancer types.

Main Methods:

• Review of early clinical trial data for adoptive cell transfer therapy using tumor-infiltrating lymphocytes.
• Summary of advancements in the characterization and application of TIL therapy.

Main Results:

• TIL therapy has demonstrated potential in treating solid tumors beyond melanoma.
• Early data suggests efficacy in renal cell carcinoma and ovarian cancer, warranting further investigation.
• Improved methodologies in T cell expansion and preparative chemotherapy regimens enhance treatment potential.

Conclusions:

• Adoptive cell transfer therapy with tumor-infiltrating lymphocytes represents a significant advancement in personalized cancer immunotherapy.
• Further research and clinical trials are essential to optimize TIL therapy for renal cell carcinoma and ovarian cancer patients.
• The targeting of neoantigens by TILs offers a rational basis for expanding this approach to new indications.